Clinical trials: Incretins
Type 2 Diabetes (T2DM)
Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
Medications that enhance the incretin effect (GLP-1 receptor agonists, tirzepatide (GIP/GLP-1 receptor agonist) and DPP-4 inhibitors) are used in treatment of patients with type 2 diabetes.
- Trial name
- NCT07852988
- Testing
- Pancreatin
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Silesian Centre for Heart Diseases
Obesity
Sugar-replacement Sweeteners, and Blood Sugar Control
Several sugar-replacement sweeteners are currently on the market, including saccharine (ex. Sweet'N Low), aspartame (ex. Equal), and sucralose (ex. Splenda).
- Trial name
- SIR (NCT01128829)
- Testing
- Water, Sucralose
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Incretin Action, Obesity
Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.
Tiny molecules (hormones) are released from the bowels and other organs to the bloodstream in response to meals in order to orchestrate the metabolism.
- Trial name
- NCT01232244
- Testing
- GLP-1 infusion, Glucagon infusion, Oxyntomodulin infusion
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Colorectal Cancer Prevention, Colorectal Adenoma
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk…
- Trial name
- PROSPECT (NCT07095517)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Insulin Secretion
Glucagon Regulation of Glucose Metabolism
Glucagon is a 30 amino acid peptide hormone that is produced exclusively in alpha-cells of the pancreatic islets. Glucagon binds to a G-protein coupled receptor and activates intracellular signaling by increasing the synthesis of…
- Trial name
- NCT04347252
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Non Alcoholic Fatty Liver Disease, Type 2 Diabetes
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without…
- Conditions
- Non Alcoholic Fatty Liver Disease, Type 2 Diabetes, Liver Cirrhosis
- Trial name
- NCT01492283
- Testing
- OGTT, IIGI
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes, Obesity
The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones
We want to evaluate the impact of the EndoBarrier Gastrointestinal Liner (DJBS) on glucose metabolism as well as gut and pancreatic hormone secretion.
- Trial name
- NCT02360878
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- Denmark
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Filip Krag Knop
Polycystic Ovary Syndrome
Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)
The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose.
- Trial name
- NCT00647023
- Testing
- metformin
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes Mellitus
Changes in Bone Turnover With Increased Incretin Hormone Exposure
The purpose of this study is to determine if the use of sitagliptin increases bone formation and reduces bone turnover in postmenopausal women with type 2 diabetes.
- Trial name
- DRTC (NCT01374568)
- Testing
- sitagliptin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Normal Weight, Overweight and Obesity
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design.
- Conditions
- Normal Weight, Overweight and Obesity, Insulin Sensitivity, Insulin Resistance
- Trial name
- NCT06487832
- Testing
- Subcutaneous GLP1-RA
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Type 2 Diabetes
Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes
We wish to evaluate the effect of long term treatment with a DPP-IV inhibitor on the function of the incretin hormones Hypothesis We hypothesize that that a gradual improvement in metabolic control induced by DPP-IV inhibitor…
- Trial name
- NCT00411411
- Testing
- Januvia
- Where
- Denmark
- Volunteers
- 49 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Septic Shock, Inflammation
Pharmacology of Exenatide in Pediatric Sepsis
Pharmacology of Exenatide in Pediatric Sepsis, PEPS is a phase 1-2 research study that will examine drug safety, drug metabolism, drug action and preliminary drug clinical effects of four does of exenatide injected every 12 hours…
- Conditions
- Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction
- Trial name
- PEPS (NCT01573806)
- Testing
- Exenatide, Exenatide vehicle
- Where
- United States
- Sponsor
- Seattle Children's Hospital
Type 2 Diabetes
Insulinotropic Effect of GLP-1 and GIP After Dexamethasone
In this study we examine whether inducing insulin resistance by dexamethasone in healthy volunteers will lead to a decreased insulinotropic effect of the hormones GLP-1 and GIP.
- Trial name
- NCT02235584
- Testing
- Dexamethasone
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Diabetes, Hyperglycemia
Insulin Secretion in Diabetes Before and After Glycemic Control
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes.
- Trial name
- NCT00469833
- Testing
- insulin glargine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Type 1 Diabetes
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects…
- Trial name
- NCT02908087
- Testing
- Victoza® (liraglutide)
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Neonatal Diabetes
Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes
Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a DNA region called the KCNJ11 gene.
- Trial name
- FoND (NCT02921906)
- Testing
- High protein meal, High carbohydrate meal, Paracetamol
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Uremia
Elimination of Incretin Hormones in Patients With Severe Kidney Failure
The prevalence of type 2 diabetes (T2D) is increasing rapidly worldwide. T2D is characterized by a severely impaired incretin effect.
- Trial name
- NCT01391884
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bo Feldt-Rasmussen
Obesity
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers.
- Trial name
- NCT07640139
- Testing
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Where
- United States
- Volunteers
- 125,000 people
- Sponsor
- Indiana University
Weight Gain
Incretin Microdosing for Cardiometabolic Health in People With HIV
The objectives of this study are as follows: Primary Objective To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs.
- Trial name
- REINFORCE (NCT07325500)
- Testing
- Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly, Dose escalation to 2 mg semaglutide weekly then no semaglutide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type2 Diabetes
Predicting Response to Incretin Based Agents in Type 2 Diabetes
Type 2 diabetes is a major and rapidly increasing health problem worldwide. Keeping the blood glucose (sugar) from going too high helps prevent complications.
- Trial name
- PRIBA (NCT01503112)
- Testing
- No intervention, observational study
- Where
- 18 sites in United Kingdom
- Volunteers
- 957 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust